dbAMP 2.0: updated resource for antimicrobial peptides with an enhanced scanning method for genomic and proteomic data

  title={dbAMP 2.0: updated resource for antimicrobial peptides with an enhanced scanning method for genomic and proteomic data},
  author={Jhih-Hua Jhong and Lantian Yao and Yuxuan Pang and Zhongyan Li and Chia-Ru Chung and Rulan Wang and Shangfu Li and Wenshuo Li and Mengqi Luo and Renfei Ma and Yuqi Huang and Xiaoning Zhu and Jiahong Zhang and Hexiang Feng and Qifan Cheng and Chunxuan Wang and Kun Xi and Li-Ching Wu and Tzu-Hao Chang and Jorng-Tzong Horng and Lizhe Zhu and Ying‐Chih Chiang and Zhuo Wang and Tzong-Yi Lee},
  journal={Nucleic Acids Research},
  pages={D460 - D470}
Abstract The last 18 months, or more, have seen a profound shift in our global experience, with many of us navigating a once-in-100-year pandemic. To date, COVID-19 remains a life-threatening pandemic with little to no targeted therapeutic recourse. The discovery of novel antiviral agents, such as vaccines and drugs, can provide therapeutic solutions to save human beings from severe infections; however, there is no specifically effective antiviral treatment confirmed for now. Thus, great… 

Figures and Tables from this paper

A review on antimicrobial peptides databases and the computational tools

This review aims to provide valuable information about different types of AMPs, their mechanism of action and a landscape of current databases and computational tools as resources to collect AMPs and beneficial tools for the prediction and design of a computational model for new active AMPs.

Traditional and Computational Screening of Non-Toxic Peptides and Approaches to Improving Selectivity

The development of in silico predictive approaches to peptide toxicity has just started, but their important contributions clearly demonstrate their potential for peptide science and computer-aided drug design.

Immunomodulatory and Allergenic Properties of Antimicrobial Peptides

The scope of this review is to summarize the current concepts and newest advances in research of the immunomodulatory activity of natural and synthetic AMPs, and to examine the prospects and limitations of their medical use.

Antimicrobial Peptides: From Design to Clinical Application

Overall, AMPs display diverse mechanisms of action against infection of pathogenic bacteria, and future research studies and clinical investigations will accelerate AMP application.

Identification of a Novel Antimicrobial Peptide From the Ancient Marine Arthropod Chinese Horseshoe Crab, Tachypleus tridentatus

The chemically synthesized peptide of Tatritin exhibited a broad spectrum of antimicrobial activity against Gram-negative and Gram-positive bacteria and fungi and may recognize and inhibit pathogenic microorganisms by directly binding to LPS, DNA, and chitin.

Machine Learning in Antibacterial Drug Design

This review focuses on the latest machine learning approaches used in the discovery of new antibacterial agents and targets, covering both small molecules and antibacterial peptides.



LAMP2: a major update of the database linking antimicrobial peptides

A database linking antimicrobial peptides (LAMPs), launched in 2013, serves as a comprehensive tool to supply exhaustive information of AMP on a single platform and has become an important tool for the discovery and transformation of AMPs as agents.

dbAMP: an integrated resource for exploring antimicrobial peptides with functional activities and physicochemical properties on transcriptome and proteome data

Abstract Antimicrobial peptides (AMPs), naturally encoded from genes and generally contained 10–100 amino acids, are crucial components of the innate immune system and can protect the host from

Designing and optimizing new antimicrobial peptides: all targets are not the same

The cellular composition is important in the AMP-target cell interaction and must be considered in the design of AMPs, too, and limitations concerning their therapeutic application, and optimization strategies for overcoming such limitations are described.

Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2

Evidence supporting the efficacy of antiviral AMPs is summarized and their potential to treat emerging viral diseases including COVID-19 is discussed.

DBAASP v3: database of antimicrobial/cytotoxic activity and structure of peptides as a resource for development of new therapeutics

Abstract The Database of Antimicrobial Activity and Structure of Peptides (DBAASP) is an open-access, comprehensive database containing information on amino acid sequences, chemical modifications, 3D

In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2

New potentially effective AMPs with antiviral properties for SARS-CoV-2 were identified, but they need experimental validation for their therapeutic effectiveness.

Chemically modified and conjugated antimicrobial peptides against superbugs.

This review summarises recent synthetic efforts and their impact on analogue design as well as their various applications in AMP development to lead to new, effective and selective solutions for the several biomedical challenges to which antimicrobial peptidomimetics are being applied.

The Potential of Antimicrobial Peptides as an Antiviral Therapy against COVID-19

The significant antiviral activity of LF makes it a potential option as an immunity enhancer, a drug or a drug conjugate with conventional antivirals, and the affordability, environmental safety, and efficiency of LFs will make them superior to all other control strategies.

The Potential of Antiviral Peptides as COVID-19 Therapeutics

Interestingly, there are AVPs demonstrated to exert prophylactic and therapeutic effects against coronaviruses (CoVs) and it is suggested that further development of this class of compounds in the face of the current pandemic threat is warranted.

Integrated evolutionary analysis reveals antimicrobial peptides with limited resistance

This work indicates that evolution of resistance against certain AMPs, such as tachyplesin II and cecropin P1, is limited, and physicochemical features that make AMPs less prone to resistance and no cross- or horizontally-acquired resistance are found.